Weight loss · Once-daily tablet
Foundayo.
Orforglipron. The GLP-1 tablet with no needles, no fasting and no timing rules.
Single pack
Everyone starts here. Your prescriber steps you up only if it suits you.
£94.99per pack
One pack, 30 daily tablets
New patient offer
- Use code FIRSTWL10for £10 off
- Consultation and dose reviews included
- No subscription, reorder when your prescriber agrees
- Next-day tracked delivery
Every price includes your consultation and clinical reviews. Each pack holds 30 daily tablets. Choose a strength to see its price.
Foundayo is a prescription-only medicine. Each pack is dispensed at the strength prescribed for you. Be cautious of any site offering Foundayo without a prescription: it is a common sign of falsified medicines.
Why Foundayo
The power of GLP-1, without the needle or the rules.
Foundayo is Eli Lilly’s new once-daily GLP-1 tablet that can be taken at any time of day, with or without food, and with no water restrictions. Because orforglipron is a small molecule rather than a peptide, it is absorbed reliably from the gut without any empty-stomach protocol. The MHRA authorised it for weight management and type 2 diabetes in August 2026, making the UK the first country in Europe to do so.
01
No fasting.
Take it with breakfast, after dinner or on the go. There is no morning fasting, no water limit and no waiting period.
02
Appetite control.
Activates the GLP-1 pathway to reduce hunger and food noise, so portion sizes fall without constant willpower battles.
03
Simple to store.
A tablet in a blister pack, stored at room temperature. Easy to keep at home, in a bag or when travelling.
04
Proven results.
In ATTAIN-1, adults who completed treatment on the highest dose lost an average of 12.4% of their body weight over 72 weeks, against 2.1% on placebo.
Get the highlights.
ATTAIN-1, 72 weeks
12.4%
average body-weight loss on the highest dose among people who completed treatment.*
1
tablet a day, at any time, with or without food or water.
6
strengths, stepped up with your prescriber. Everyone starts on 0.8mg.
24 to 48 hours
from your assessment to your first tablet.
*ATTAIN-1, 72 weeks on the highest dose among participants who completed treatment. Averages: individual results vary.
The evidence
What the ATTAIN-1 trial showed.
A 72-week phase 3 study of 3,127 adults with obesity or overweight, comparing orforglipron with placebo alongside diet and physical activity. These are averages; individual results vary and no treatment can guarantee a specific outcome.
Average body-weight change in the trial
- Foundayo highest dose, completed treatment-12.4%
- Foundayo highest dose, all participants-11.1%
- Placebo with the same diet and activity-2.1%
- 3,127
- adults in the trial
- 72
- weeks of treatment
- 12.4%
- average loss on the highest dose, completed treatment
- 2.1%
- with placebo and the same lifestyle programme
Weight loss over 72 weeks on the 36mg trial dose, which corresponds to the authorised 17.2mg tablet strength (licensed strengths are expressed as the free base). Wharton S et al., NEJM 2025.
Your dosing journey
A gradual build-up, exactly as licensed.
Foundayo starts low and increases in stages, with at least a month at each step. This titration gives your body time to adjust and keeps side effects manageable. Your prescriber agrees the maintenance dose that suits you; not everyone needs the highest strength.
Month 1
0.8mg
Starting dose, to get used to treatment
Month 2
2.5mg
Only if tolerated well
Month 3
5.5mg
Only if tolerated well
Month 4
9mg
Maintenance dose for many
Month 5
14.5mg
Only if tolerated well
Month 6+
17.2mg
Maximum dose
Doses are increased no faster than monthly, and only if you are tolerating treatment well. Many people stabilise on a middle dose rather than always climbing to the maximum. The schedule follows the UK Summary of Product Characteristics.
Getting started
Three simple steps.
From your assessment to your first tablet in 24 to 48 hours.
- 1
Free online consultation.
A confidential health questionnaire, completed in minutes. Nothing is charged at this stage.
- 2
Prescriber review.
A UK prescriber checks your suitability, medical history and current medicines, and confirms your starting dose, usually the same day.
- 3
Discreet delivery.
Dispensed by our registered pharmacy and sent next day in plain, tracked packaging. No cold chain needed.
Suitability
Is Foundayo right for you?
Foundayo is a prescription weight-management medicine used alongside diet and exercise, not a quick fix. Under its UK licence it is for adults with a BMI of 30 or above, or between 27 and 30 with at least one weight-related condition such as high blood pressure, prediabetes or obstructive sleep apnoea. It is also licensed to improve blood-sugar control in type 2 diabetes.
Every order begins with a confidential online assessment reviewed by our prescribing team. If Foundayo is not clinically appropriate for you, we will say so and suggest alternatives. The clinical review is a legal requirement and an important safeguard, not a formality.
Quick check before you start
- You are an adult (18 or over) living in the UK
- BMI of 30 or above, or 27 to 30 with a weight-related condition
- Not pregnant, breastfeeding or planning pregnancy
- No history of pancreatitis or medullary thyroid cancer
- Ready to make diet and activity changes alongside treatment
At a glance
- Active ingredient
- Orforglipron (GLP-1), a small molecule
- Doses
- 0.8mg to 17.2mg, stepped monthly
- Form
- Tablets, 30-day pack, stored at room temperature
- Licence
- MHRA-authorised, August 2026, the first in Europe
Safety
Side effects and how they are managed.
As with other GLP-1 medicines, the most common side effects are gastrointestinal: nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. They are most noticeable when starting treatment or increasing the dose, and for most people they ease as the body adjusts.
01
Eat smaller, lower-fat meals and stay well hydrated to ease nausea, which usually settles within a few weeks of each dose change.
02
Foundayo must not be used in pregnancy or while breastfeeding. Tell your prescriber if you are planning a pregnancy.
03
Tell your prescriber about every medicine you take, including the contraceptive pill, so timing and doses can be checked.
04
Seek urgent medical help for severe or persistent abdominal pain, ongoing vomiting or signs of dehydration.
For a full list of side effects, see the patient information leaflet supplied with your pack. Report suspected side effects through the MHRA Yellow Card scheme.
Why Cuva
Safe, regulated care you can trust.
Cuva Health is a pharmacy registered with the General Pharmaceutical Council, operating under the supervision of our Superintendent Pharmacist. Every pack we supply is a genuine, MHRA-authorised medicine sourced through the regulated UK supply chain, prescribed only after clinical review.
UK-regulated prescribing
A GPhC-registered pharmacy supervised by a named Superintendent Pharmacist.
Fast online consultation
Free assessment, reviewed by a UK prescriber, usually within one working day.
Discreet delivery
Plain, tracked packaging, next day to most UK addresses.
Human support
Real people on WhatsApp to help with side effects and taking your tablets.
Registered Pharmacy GPhC 9012581 · Superintendent Pharmacist Irfan Mahmud (GPhC 2080386)
Foundayo questions? Ask a pharmacist.
Straight answers about orforglipron, the consultation, dosing, storage and delivery, written by our clinical team.
Or email support@cuvahealth.co.uk
Frequently asked
What is Foundayo?
Foundayo is the brand name for orforglipron, Eli Lilly’s once-daily GLP-1 tablet. It is a small molecule rather than a peptide, so it is absorbed reliably from the gut without any empty-stomach rules. The MHRA authorised it in August 2026 for weight management in adults alongside diet and physical activity, and for type 2 diabetes.
Do I need to take it on an empty stomach?
No. Unlike the semaglutide tablet, Foundayo has no food, water or timing rules. Take one tablet a day whenever suits you, with or without food, and try to keep to roughly the same time each day.
How much weight could I lose?
In the ATTAIN-1 trial, adults who completed treatment on the highest dose lost an average of 12.4% of their body weight over 72 weeks, and 11.1% across all participants including those who stopped early. For someone weighing 100kg that is roughly 11 to 12kg, though results vary from person to person.
How does it work?
Orforglipron activates the GLP-1 receptor, the same pathway as semaglutide and tirzepatide. It helps you feel full sooner, stay satisfied for longer and quietens persistent food cravings, the food noise that makes dieting so hard, so you eat less without constant willpower battles.
How is Foundayo different from the Wegovy tablet?
Both are once-daily GLP-1 tablets. The Wegovy tablet contains semaglutide and must be taken on an empty stomach with a small amount of water, then a 30-minute wait; Foundayo contains orforglipron and can be taken at any time with or without food. Trial results are higher for semaglutide, so your prescriber will discuss which suits your goals and routine.
Why does the dose start low and increase?
Starting at 0.8mg and stepping up monthly gives your body time to adjust and keeps side effects manageable. Doses are only increased if you are tolerating treatment well, and many people settle on a middle dose rather than the maximum.
How do I store it?
At room temperature in its original blister pack, away from moisture. No fridge is needed, so it is easy to keep at home, in a bag or when travelling.
What are the most common side effects?
Nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain, most noticeable when starting or increasing a dose and easing for most people as the body adjusts. Rarer but serious risks include pancreatitis, so seek help quickly for severe or persistent stomach pain. Your medical history is always reviewed before treatment begins.
What happens if I miss a dose?
Take it as soon as you remember that day. If it is already the next day, skip the missed dose and carry on as usual. Do not take two tablets on the same day.
Will I regain weight if I stop?
Some regain is common after stopping any weight loss medicine, because appetite returns. The habits built during treatment make a real difference, and your prescriber can plan a gradual step-down with you rather than stopping abruptly.
Can I switch to Foundayo from another treatment?
Yes, where it is clinically appropriate. Tell us your current medicine and dose during the consultation and upload a photo of your prescription or packaging, and your prescriber will agree the right Foundayo dose to move to.
Sources
- Wharton S et al. Orforglipron, a Once-Daily Oral GLP-1 Receptor Agonist, in Adults with Obesity (ATTAIN-1). NEJM 2025.
- MHRA, GOV.UK. Orforglipron authorised for weight management and type 2 diabetes, August 2026.
- emc. Foundayo Summary of Product Characteristics, sections 4.2, 4.8 and 6.4.
- MHRA Yellow Card scheme.
Ready when you are.
Start with a short, free online assessment. A UK prescriber takes it from there.
Not for emergencies. Call 999, or NHS 111 for urgent advice.